Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Myriad Genetics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Myriad Genetics Inc (MYGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Glenview Capital Larry Robbins | 4,943,595 | $105,397,445 | -7% | 1.84% |
| 2. | Millennium Management Israel Englander | 4,074,038 | $86,858,490 | +18% | 0.03% |
| 3. | Citadel Investment Group Ken Griffin | 1,366,547 | $29,134,782 | +18% | 0% |
| 4. | D E Shaw D. E. Shaw | 1,266,113 | $26,993,529 | -30% | 0.02% |
| 5. | Point72 Asset Management Steve Cohen | 778,196 | $16,591,139 | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.62 | 15,000 | Director | 66,790 | 2020-11-11 | Filing | |
| $25.60 | 5,860 | Director | 54,150 | 2019-12-13 | Filing | |
| $23.46 | 1,750 | Director | 2,050 | 2019-11-07 | Filing | |
| $23.46 | 5,250 | Director | 64,353 | 2019-11-07 | Filing | |
| $18.57 | 400 | Director | 42,524 | 2017-02-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.05 | 3,788 | Director | 32,917 | 2024-06-04 | Filing | |
| $22.04 | 3,788 | Director | 36,705 | 2024-06-03 | Filing | |
| $25.07 | 75,000 | Officer, Director | 1,066,166 | 2024-05-15 | Filing | |
| $25.21 | 95,000 | Officer, Director | 1,141,166 | 2024-05-14 | Filing | |
| $25.13 | 57,844 | Officer, Director | 1,236,166 | 2024-05-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,658,349 | $280,560,800 | 0% | |
| 2. | 9,954,233 | $190,524,020 | 0% | |
| 3. | 7,219,706 | $138,185,172 | 0.02% | |
| 4. | 4,700,631 | $89,970,077 | 0% | |
| 5. | 3,913,913 | $74,912,295 | 0.37% |
News See All
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript
Myriad Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $0.02. Myriad Genetics, Inc.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Call Transcript
Matt Scalo: Good afternoon and welcome to Myriad Genetics Third Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Myriad Genetics Second Quarter 2023 Financial Earnings Call [Operator Instructions]. As a reminder, this conference is being recorded Thursday, August 3, 2023.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2023 Earnings Call Transcript
Matthew Scalo: Okay. Good afternoon, and welcome to the Myriad Genetics' First Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Myriad Genetics Fourth Quarter 2022 Financial Earnings Conference Call. During the presentation, all participants will be in a listen-only mode.
12 Biggest Genomics Companies In The World
In this article, we will discuss the 12 Biggest Genomics Companies In The World.
10 Best Healthcare Stocks to Buy According to Billionaire Larry Robbins
This article discusses the top 10 healthcare stock picks of billionaire Larry Robbins’ hedge fund Glenview Capital Management.
Were Hedge Funds Right About Myriad Genetics, Inc. (MYGN)?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Billionaire Hedge Funds
